FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
Season 3, Episode 26, Aug 03, 2020, 08:04 PM
In an interview with OncLive, Dr. Wang discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.